Evidence map›Paper›PMID 38973951›Full record

ArticleTranslational lung cancer research2024

Clinical impact of

Jiahao Jiang, Mark F Berry, Natalie S Lui, Douglas Z Liou, Winston L Trope, Leah M Backhus, Joseph B Shrager

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Translational lung cancer research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Jiahao JiangDivision of Thoracic Surgery, Department of Cardiothoracic Surgery, Stanford University, Stanford, CA, USA.
Mark F BerryDivision of Thoracic Surgery, Department of Cardiothoracic Surgery, Stanford University, Stanford, CA, USA.
Natalie S LuiDivision of Thoracic Surgery, Department of Cardiothoracic Surgery, Stanford University, Stanford, CA, USA.
Douglas Z LiouDivision of Thoracic Surgery, Department of Cardiothoracic Surgery, Stanford University, Stanford, CA, USA.
Winston L TropeDivision of Thoracic Surgery, Department of Cardiothoracic Surgery, Stanford University, Stanford, CA, USA.
Leah M BackhusDivision of Thoracic Surgery, Department of Cardiothoracic Surgery, Stanford University, Stanford, CA, USA.
Joseph B ShragerDivision of Thoracic Surgery, Department of Cardiothoracic Surgery, Stanford University, Stanford, CA, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Epidermal growth factor receptor (EGFR) and Kirsten rat sarcoma (KRAS) are the two most common oncogenic drivers in lung adenocarcinoma, and their roles still need further exploration. Here we aimed to compare the clinical impact of Methods: Clinicopathologic and genomic data were collected for patients who underwent resection of lung adenocarcinoma from 2008 to 2022 at Stanford University Hospital. Retrospective review was performed in 241 patients whose tumors harbored Results: We confirm that compared with Conclusions: Resected lung adenocarcinomas with

Indexed as

Epidermal growth factor receptor (EGFR)Kirsten rat sarcoma (KRAS)lung adenocarcinomamultifocal pulmonary nodules

Identifiers

PMID38973951
PMCPMC11225054

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.